所属 埼玉医科大学 医学部 国際医療センター 造血器腫瘍科 職種 助教
|Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine
|正式名：Leukemia Research Reports
|◎Daisuke Okamura, Akira Matsuda, Maho Ishikawa, Tomoya Maeda, Ken Tanae, Mika Kohri, Naoki Takahashi, Nobutaka Kawai, Norio Asou, Masami Bessho
|Azacitidine was administered to a 74-year-old man with MDS-F at a dose of 75 mg/m2/daily subcutaneously for 7 days every 28 days. Hematologic improvements were observed according to the IWG 2006 criteria after 8 cycles of the aza treatment, and complete remission was achieved after 14 cycles. The grade of myelofibrosis was also improved. The therapeutic activity of aza was confirmed in our MDS-F patient.